PepGen is a biotechnology company that is focused on developing transformative therapies for patients with neuromuscular diseases. The company's lead product candidate, PGN-001, is a gene therapy that is designed to treat Duchenne muscular dystrophy (DMD), a rare and fatal genetic disorder that affects approximately 1 in 3,500 boys worldwide. PepGen was founded in 2018 and is headquartered in Cambridge, Massachusetts.